Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 1/20 | 0.69 |
| ▸ | CA12 | O43570 | 5/20 | 0.59 |
| ▸ | CA1 | P00915 | 5/20 | 0.59 |
| ▸ | CA2 | P00918 | 5/20 | 0.59 |
| ▸ | CA7 | P43166 | 5/20 | 0.59 |
| ▸ | CA9 | Q16790 | 5/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.59 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.59 |
| ▸ | EGFR | P00533 | 2/20 | 0.57 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6883774 | 0.90 | HSD17B1 (0.59) | HSD17B1CA12CA1CA2CA7 | |
| SCHEMBL28255681 | 0.88 | SLC2A1 (0.63) | HSD17B1CA12CA1CA2CA7 | |
| SCHEMBL2773084 | 0.87 | CA12 (0.58) | HSD17B1CA12CA1CA2CA7 | |
| SCHEMBL26571944 | 0.85 | TDP1 (0.61) | HSD17B1CA12CA1CA2CA7 | |
| SCHEMBL2770758 | 0.84 | HSD17B1 (0.56) | HSD17B1CA12CA1CA2CA7 | |
| SCHEMBL28661980 | 0.84 | HSD17B1 (0.65) | HSD17B1CA12CA1CA2CA7 | |
| SCHEMBL28905197 | 0.84 | SLC2A1 (0.59) | HSD17B1CA12CA1CA2CA7 | |
| SCHEMBL22824130 | 0.83 | SLC2A1 (0.57) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6102320 | 0.83 | SLC2A1 (0.58) | HSD17B1CA12CA1CA2CA7 | |
| SCHEMBL26571353 | 0.83 | SLC2A1 (0.58) | HSD17B1CA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113748021-B | Method for producing liquid crystal polyester processed product | 本州化学工业株式会社 | 2024-07-05 | — | — | CN | claimed |
| CN-113748021-B | Method for producing liquid crystal polyester processed product | 本州化学工业株式会社 | 2024-07-05 | — | — | CN | disclosed |
| CN-113748021-A | Method for producing liquid crystal polyester processed product | 本州化学工业株式会社 | 2021-12-03 | — | — | CN | disclosed |
| US-8106077-B2 | Compounds and methods for modulating FXR | ELI LILLY AND COMPANY (US) | 2012-01-31 | — | — | US | disclosed |
| US-7846960-B2 | FXR agonists | ELI LILLY AND COMPANY (US) | 2010-12-07 | — | — | US | disclosed |
| EP-2029547-B1 | FXR AGONISTS | LILLY CO ELI (US) | 2010-04-28 | — | — | EP | disclosed |
| EP-2029558-B1 | COMPOUNDS AND METHODS FOR MODULATING FXR | LILLY CO ELI (US) | 2010-03-10 | — | — | EP | disclosed |
| US-20090270460-A1 | FXR AGONISTS | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2009-10-29 | — | — | US | disclosed |
| US-20090093524-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2009-04-09 | — | — | US | disclosed |
| EP-2029547-A1 | FXR AGONISTS | ELI LILLY AND COMPANY (US) | 2009-03-04 | — | — | EP | disclosed |
| EP-2029558-A2 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007140183-A1 | FXR AGONISTS | ELI LILLY AND COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007140174-A2 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |
| EP-0888357-A1 | AZASPIRO DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997034900-A1 | AZASPIRO DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 1997-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270460-A1 | FXR AGONISTS | NR1H4, SLC10A1, GPBAR1 | HSD17B1 113/4885CA12 4483/4885CA1 4489/4885 |
| US-20090093524-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NR1H4, SLC10A1, FXR1 | HSD17B1 119/4885CA12 4104/4885CA1 3660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.